CALA Calithera Biosciences Inc.

3.81
-0.16  -4%
Previous Close 3.97
Open 3.99
Price To Book 1.47
Market Cap 204,882,377
Shares 53,774,902
Volume 112,884
Short Ratio
Av. Daily Volume 278,633

NewsSee all news

  1. Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019

    -Results from ENTRATA Phase 2 trial of telaglenastat in patients with advanced renal cell carcinoma (RCC) accepted as Late Breaking Oral Presentation- -Data from INCB001158 clinical program accepted as Oral

  2. Calithera to Participate in Wells Fargo Healthcare Conference and Citi 14th Annual Biotech Conference

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial ongoing but will not pursue development.
CB-839 with paclitaxel
Triple negative breast cancer
Phase 2 data to be presented at ESMO September 28, 2019, 8:30am CET.
CB-839 + AFINITOR (everolimus)‎ - ENTRATA
Clear cell renal cell carcinoma
Phase 1 oral presentation at ASCO, June 5, 2017.
CX-1158-101
Solid tumors - cancer
Phase 1/2 enrollment commenced August 2016. Oral presentation November 11, 2017 at 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
CB-839 + nivolumab
Renal cell carcinoma, malignant melanoma and non-small cell lung cancer
Phase 2 top-line data due 2H 2020.
CB-839 + Cabozantinib (CANTATA)
Renal cell carcinoma
Phase 2 portion of trial is ongoing.
CB-839 + Panitumumab
Colorectal cancer
Phase 1 poster at ASCO June 4, 2018 8am.
CB-839 + Capecitabine
Solid tumors
Phase 1 presentation at ASCO June 2018. PFS 26 weeks.
CB-839 plus capecitabine
Solid tumors
Phase 1/2 trial initiation announced March 26, 2019.
CB-839 plus talazoparib
Triple negative breast cancer
Phase 1/2 data due at ESMO September 29, 2019.
INCB001158
Solid tumors
Phase 1/2 trial to be initiated 2Q 2019.
Ibrance and talazoparib + CB-839
KRAS mutated NSCLC
Phase 1 trial initiation announced February 21, 2019 with trial completion 2019.
CB-280
Cystic fibrosis
Phase 1/2 initiation announced July 2, 2019.
Telaglenastat (CB-839) + palbociclib
KRAS-mutated colorectal cancer (CRC) and KRAS-mutated non-small cell lung cancer (NSCLC)

Latest News

  1. Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019

    -Results from ENTRATA Phase 2 trial of telaglenastat in patients with advanced renal cell carcinoma (RCC) accepted as Late Breaking Oral Presentation- -Data from INCB001158 clinical program accepted as Oral

  2. Calithera to Participate in Wells Fargo Healthcare Conference and Citi 14th Annual Biotech Conference

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the